Observational studyClinical rheumatology2025
Ultrasonographic measurement of talar cartilage thickness in patients with rheumatoid arthritis and healthy controls.
Observational study in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to compare talar cartilage thickness in patients with RA and healthy controls and to investigate its association with clinical and demographic variables.
methodThirty-seven healthy controls and 63 patients with RA diagnosed using the American College of Rheumatology's (ACR) 2010 criteria were included in this cross-sectional observational study. All participants' age, gender, and body mass index (BMI) were recorded. The hospital record system's data was retrieved for the patient group, including medication use, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), seropositivity, and disease duration. VAS was used to assess pain, and DAS-28 was used to assess disease activity. Talar cartilage thickness measurement was performed by the same doctor as the ultrasound. Descriptive statistics of the data obtained from the study were given by mean, standard deviation for numerical variables, and frequency and percentage analysis for categorical variables. Mann-Whitney U test was used for categorical variables with two groups, and Kruskal Wallis test was used for categorical variables with three or more groups in the comparison of parameters according to categorical variables. Analyses were performed with the help of SPSS 22.0 program. p < 0.05 significance level was selected.
resultsThere was no discernible difference between the patient and control groups in terms of age, height, weight, gender, or BMI values (p > 0.05). Talar cartilage thickness did not significantly correlate with age, BMI, ESR, CRP, CCP, DAS-28 RF, number of swollen joints, or sensitive joints (p > 0,05). However, talar cartilage thickness, VAS, HAQ values, and disease duration were significantly correlated negatively (p < 0.05).
conclusionOur study showed that there is a significant decrease in talar cartilage thickness in RA patients, and this decrease is associated with disease duration, pain severity, and functional impairment. Key Points • Talar cartilage thickness was found to be lower in RA patients compared to the control group • Talar cartilage measurements were negatively correlated with disease duration, VAS and HAQ scores • Talar cartilage thickness may be a potential biomarker for assessing early joint damage and monitoring disease progression in RA.
Indexed as
Identifiers
41076467What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.